
Work Here?
Opentrons makes affordable, user-friendly lab automation systems for biology and life sciences. Its OT-2 is a liquid-handling robot that automates pipetting by moving liquids between containers, guided by software and consumables. It competes by targeting smaller labs with lower cost and easier setup, unlike traditional high-cost systems. Its goal is to make automation practical and accessible for a wide range of customers, speeding up experiments and throughput.
Industries
Robotics & Automation
Hardware
Biotechnology
Company Size
51-200
Company Stage
Series C
Total Funding
$230.8M
Headquarters
New York City, New York
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$230.8M
Above
Industry Average
Funded Over
5 Rounds
Industry standards
Opentrons introduces dynamic simulation, visualization for AI-generated lab workflows. A researcher a Boston University's DAMP Lab works with an Opentrons Flex robot. Credit: Opentrons Labworks Inc. Pharmaceutical companies and research institutions are using artificial intelligence to design robotic experiments at scale, but they need to know if AI-generated instructions will execute correctly before handling valuable samples and reagents. Opentrons Labworks Inc. today announced Protocol Visualization for Opentrons Flex, a new simulation and visualization capability. The feature allows scientists to simulate and inspect robotic protocols in a dynamic virtual environment before running them on the Flex system. The interface enables users to observe each step of an automated workflow. "This capability gives researchers a dynamic way to simulate and inspect robotic execution before an experiment begins, creating a clearer bridge between computational design and physical laboratory workflows," stated James Atwood, CEO of Opentrons. "As AI systems propose more experiments, researchers need infrastructure that makes those experiments understandable, inspectable, and repeatable before they reach the bench." Founded in 2013, Opentrons said it has more than 10,000 robotic systems deployed globally, including installations at leading research universities and many of the world's largest biopharma companies. Visualization tool runs on existing protocols. Opentrons said it supports protocols authored across its software ecosystem, including OpentronsAI, the Python Protocol API, and the Protocol Designer application. Scientists can inspect workflows and observe changes in liquid levels at microliter scale. The system also includes a Slot Spotlight view that provides additional detail for individual deck locations. This allows users to monitor well volumes and module conditions throughout a run, the New York-based company explained. For laboratories developing complex automation workflows, this level of inspection may support faster debugging and protocol refinement. Scientists can review workflows offline without interrupting active laboratory operations, noted Opentrons. The new capability will be available through Opentrons App Version 9.0, scheduled for release in April 2026. Opentrons CEO explains how lab feature works. Atwood replied to the the following questions from The Robot Report: Is Opentrons' simulation and inspection layer hardware-agnostic? If not, is there a specific set of procedures it covers? Atwood: The simulation and visualization environment is designed specifically for protocols written for the Opentrons Flex robotic platform. The system takes any valid Flex protocol and allows the user to simulate and inspect how the robot will execute it. That includes everything from simple liquid transfers to complex workflows with thousands of robotic actions. Scientists can step through protocols of virtually any size, from a handful of steps to workflows containing 10,000 or more actions, and observe pipetting, liquid handling, labware movements, and module states before running the experiment. Because the simulation environment mirrors the Flex execution environment, it allows researchers to understand exactly how the robot will behave before committing reagents, consumables, and instrument time. Why has the pharmaceutical industry been slow to address AI verification problems? How serious are they? Atwood: Part of the challenge is that much of the expertise required to verify experiments has historically been tacit laboratory knowledge rather than formalized data. A lot of experimental troubleshooting relies on what experienced scientists notice at the bench: how a liquid behaves in a well plate, how a reaction looks as it proceeds, or whether something subtle seems off in the workflow. That kind of observational expertise is difficult to encode directly into AI systems. In other words, the AI doesn't know what it doesn't know. Many of the verification challenges only become visible when experiments interact with the physical world. This is why the industry is now focusing on what we call physical AI: systems that combine language models with perception and real-world data Instead of relying only on documentation or protocols, these systems increasingly need visual data, sensor data, and execution data from real experiments. The verification challenge is serious, but it's also solvable as automation platforms generate more structured experimental data and as AI models begin interacting directly with laboratory environments. Protocol Visualization for Opentrons Flex is designed to test robotic biopharma experiments at scale before execution. Source: Opentrons Can you describe how Opentrons' generative AI works? How do you ensure repeatability and explainability? Atwood: The generative AI behind OpentronsAI translates scientific intent into executable automation protocols. At a high level, the system uses large language models combined with a retrieval-augmented generation (RAG) architecture. The models reference Opentrons' documentation and a large internal knowledge base of laboratory protocols and automation workflows developed and verified by Opentrons over many years. When a scientist describes an experiment in natural language, the system retrieves relevant examples and structured knowledge from this database and uses that context to generate a protocol suitable for execution on the robot. Repeatability and explainability come from several layers of control. The protocols generated are fully inspectable Python-based automation workflows, meaning researchers can review, edit, and verify the steps before execution. Structured prompting also ensures that the input captures the information required to produce reliable automation protocols. In practice, the AI helps scientists move faster from experimental idea to executable workflow, while still allowing human oversight and inspection before the experiment runs. Did Opentrons work with specific lab automation vendors and end users to develop this offering, and if so, what did it learn? Atwood: The AI capability was developed with extensive feedback from a cohort of beta users, including researchers building automated workflows on the Flex platform. One of the key insights was that as AI-generated protocols become more complex, researchers need better ways to inspect, understand, and debug workflows before execution. In parallel, Opentrons is also collaborating with AI and robotics partners, including NVIDIA and HighRes Biosolutions as part of broader efforts to connect AI systems with physical laboratory automation. These collaborations are helping push the ecosystem toward physical AI, where autonomous systems can reason about experiments, interact with robotic platforms, and adapt based on real-world feedback. How is autonomous science evolving, and what challenges remain? Atwood: The trajectory is toward increasingly autonomous laboratories, where AI systems can design experiments, execute them through robotics, observe outcomes, and refine future experiments based on the results. Achieving that requires combining several capabilities: * Reasoning systems, often powered by large language models, that can plan experiments * Perception systems such as vision-language models that allow AI to observe what is happening in real experiments * Physical AI systems that connect those models to laboratory automation platforms so experiments can be executed in the real world Opentrons provides the infrastructure layer for this development, connecting AI-driven intent to reliable execution on automated lab hardware. The biggest challenge is building reliable feedback loops between digital intelligence and physical experiments. Unlike purely digital domains, biology requires capturing structured data from real laboratory environments: visual observations, instrument outputs, and environmental signals. There has been rapid progress in this area, including advances in simulation and digital twin environments like NVIDIA Isaac, which help train and test AI systems before they interact with real laboratory hardware.
HighRes and Opentrons showcase 'industry's first' AI agent-to-agent lab automation workflow. Discover more AI Technology Consulting HighRes, a laboratory automation and orchestration software provider, and Opentrons Labworks, a laboratory robotics company building the physical infrastructure for AI-driven autonomous science, have agreed a strategic partnership to co-develop "the industry's first AI agent-to-agent laboratory workflow". Together, the companies are introducing a new model for workflow automation that connects intuitive, modular robotics with enterprise-grade orchestration and AI-ready infrastructure. They demonstrated their innovation at the recent Society for Laboratory Automation and Screening event. This collaboration brings Opentrons' flexible, high-throughput Opentrons Flex robotic platforms and OpentronsAI, together with the FlexPod Configurable Lab Automation Platform and Cellario, HighRes' industry-leading scheduling and orchestration software, enabling scientists to adopt automation quickly and scale seamlessly as workflows grow in complexity. "We see Opentrons as an innovative partner that has driven democratization of lab automation through cost-effective, capable liquid handling and more accessible, agentic protocol creation," said Ira Hoffman, CEO of HighRes. "We share that philosophy, and together we're unlocking greater speed and access for scientists while maintaining the reliability and repeatability life science organizations demand." Discover more AI Powered Analytics Robotics kits 3D printers "This is a joint effort to rethink how automation actually gets used in real labs," said James Atwood, CEO of Opentrons. "With HighRes, we're creating a tightly integrated system where AI-driven intent is translated directly into reliable, physical execution at the bench." Debuting the first agent-to-agent workflow at SLAS. At SLAS 2026, HighRes and Opentrons held a live demonstration of the agent-to-agent lab workflow, showing how autonomous software agents communicate across platforms to plan and execute experiments using natural language. The demonstration featured: * Agent-to-agent orchestration, leveraging HighRes orchestration software, OpentronsAI, and the Opentrons MCP server to generate semi-automated qPCR workflows from natural-language input * A unified digital lab experience, integrating experiment planning, execution, and data management * A scalable automation pathway, extending accessible, bench-friendly robotics into fully orchestrated lab ecosystems * An AI-ready operational model, unifying data, devices, and decisions through a shared orchestration layer Designed for interoperability and scale. Interoperability underpins the partnership, with both companies committed to open, extensible APIs and transparent system architectures. This approach enables Opentrons' robotic platforms to operate alongside instruments from multiple vendors within HighRes' orchestration environment, say the companies. Discover more Industry Insights Report Warehouse Automation Consulting
Opentrons and NVIDIA advance physical AI robotics for autonomous labs. Opentrons Labworks Inc., a leading laboratory robotics company focused on enabling AI-driven autonomous science, is rapidly accelerating the development and deployment of physical AI-powered lab automation in collaboration with NVIDIA. Through this strategic integration, Opentrons is leveraging the NVIDIA Isaac and NVIDIA Cosmos platforms to generate training data specifically designed for physical AI models operating in real laboratory environments. This partnership marks an important step forward because Opentrons brings a rare combination of real-world scale and scientific expertise. The company has already deployed more than 10,000 robotic systems globally across top research universities and major biopharma organizations. Along with this extensive installed base, Opentrons also contributes deep experimental knowledge gained from both its own robotics platforms and a broad ecosystem of third-party laboratory instruments. By working closely with NVIDIA, Opentrons is effectively bridging the gap between simulation and reality. As a result, physical AI can transition from theoretical modeling into practical, everyday laboratory workflows. This integration also supports NVIDIA BioNeMo, which provides the foundation for training and deploying AI models aimed at biological discovery. Meanwhile, Opentrons supplies the standardized physical execution layer needed to connect digital scientific design with experimental validation in the lab. Until now, AI in drug discovery has largely remained limited to prediction-based tasks. For instance, AI systems can propose molecular structures, identify potential drug targets, and analyze massive datasets. However, experimental execution has continued to be the biggest bottleneck in turning these predictions into real discoveries. Opentrons addresses this challenge by standardizing laboratory execution and producing high-quality training data from real wet-lab operations. Consequently, AI systems can continuously learn directly from experimental results, creating a powerful feedback loop that drives faster innovation. "We see a future where physical AI unlocks autonomous experimental execution throughout laboratory environments," said James Atwood, CEO of Opentrons. "AI models and agents propose a hypothesis and experimental plan; our systems execute that experiment. The results are then fed back to the AI in a closed loop to refine the experiment further. When that cycle runs continuously across thousands of labs, discovery timelines compress from years to weeks." NVIDIA also emphasized the importance of connecting computational intelligence with real-world validation. "Connecting computational models with experimental validation is essential to accelerating AI-driven drug discovery," said Stacie Calad-Thomson, North American Business Development Lead for Healthcare and Life Sciences at NVIDIA. "With NVIDIA AI, Opentrons provides the standardized physical infrastructure that turns experimental designs into consistent, reproducible results - helping generate the training data needed to develop physical AI models that can operate across diverse laboratory environments." Ultimately, Opentrons continues to expand its role in lab automation by building AI-enabled robotics that streamline workflows from antibody discovery to genomics and proteomics. With systems already deployed across every top-20 U.S. research university and 14 of the top 15 global biopharma companies, Opentrons now operates the world's largest standardized network of laboratory automation bringing the promise of autonomous science closer to reality.
Opentrons and NVIDIA partner to develop physical AI for laboratory robotics. What you should know. * The Partnership: Opentrons Labworks, the company behind the ubiquitous pipette robots found in labs worldwide, is partnering with NVIDIA to accelerate the development of "Physical AI." * The Integration: By combining NVIDIA's Isaac and Cosmos platforms with Opentrons' fleet of 10,000+ robots, the companies aim to create a "closed loop" where AI doesn't just predict drug targets (via NVIDIA BioNeMo) but physically validates them in the wet lab. * The Goal: The collaboration addresses the biggest bottleneck in modern biotech: experimental execution. By standardizing this layer, the partnership aims to compress discovery timelines from years to weeks by allowing AI models to learn continuously from real-world results. Solving the "execution bottleneck" The timing of this partnership is critical. The industry has reached a tipping point where computational models (like those built on NVIDIA BioNeMo) can generate hypotheses faster than human scientists can test them. Experimental execution has become the rate-limiting step. Opentrons is uniquely positioned to solve this. Unlike legacy automation giants that build bespoke, million-dollar systems for massive pharma, Opentrons democratized the field with affordable, API-driven robots. They now have over 10,000 systems deployed across every top-20 U.S. research university and 14 of the top 15 global biopharma companies. This fleet represents the world's largest standardized network of lab automation - essentially, a distributed factory for generating the "ground truth" data that physical AI models need to learn. Closing the loop. The technical vision is a "closed loop" system: * Design: An AI agent (powered by NVIDIA BioNeMo) proposes a molecular structure and an experimental plan. * Execution: Opentrons robots (trained via NVIDIA Isaac/Cosmos) physically execute the experiment in the lab. * Learning: The results are fed back into the model to refine the next hypothesis. "Connecting computational models with experimental validation is essential," said Stacie Calad-Thomson, NVIDIA's healthcare lead. By providing the "standardized physical infrastructure," Opentrons ensures that the data fed back into the AI is consistent and reproducible - two qualities often lacking in manual lab work.
HighRes and Opentrons have announced a strategic partnership to develop the industry's first AI agent-to-agent laboratory workflow, combining robotics with AI-driven orchestration software. The collaboration integrates Opentrons' Flex robotic platforms and OpentronsAI with HighRes' Cellario scheduling and orchestration software. The partnership aims to enable scientists to adopt automation quickly whilst scaling workflows as complexity increases. At SLAS 2026, the companies will demonstrate a live agent-to-agent lab workflow that uses natural language to plan and execute experiments, featuring semi-automated qPCR workflows. "We're creating a tightly integrated system where AI-driven intent is translated directly into reliable, physical execution at the bench," said James Atwood, CEO of Opentrons. The collaboration seeks to unite accessible robotics with enterprise-grade orchestration for life science organisations.
Find jobs on Simplify and start your career today
Industries
Robotics & Automation
Hardware
Biotechnology
Company Size
51-200
Company Stage
Series C
Total Funding
$230.8M
Headquarters
New York City, New York
Founded
2014
Find jobs on Simplify and start your career today